Xenon (XENE) has released an update.
Xenon Pharmaceuticals Inc. presented compelling long-term data and reported quality of life improvements for adults with focal onset seizures at the 15th European Epilepsy Congress. Their drug, Azetukalner, shows more than a 90% reduction in seizure frequency in patients and has been linked to periods of seizure freedom lasting a year or longer.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
